Dergiler / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 1

An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment

Sayfa
22–27
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

From this point, these boron derivatives may provide a novel therapeutic approach for breast cancer treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: We aimed to investigate the distribution of immunoreactivities of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inducible NOS (iNOS) on breast cancer cells in response to treatment with boron derivatives.
📊
Temel Bulgular & Veri:Methods: We initially analyzed the cytotoxic effect and IC50 value of boron by MTT assay.
💡
Sonuç & Katkı:From this point, these boron derivatives may provide a novel therapeutic approach for breast cancer treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: We aimed to investigate the distribution of immunoreactivities of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inducible NOS (iNOS) on breast cancer cells in response to treatment with boron derivatives. Methods: We initially analyzed the cytotoxic effect and IC50 value of boron by MTT assay. For the evaluation of the angiogenesis, expression level of antibodies was detected to following boron derivatives such as boric acid, boron penta (BP), and T-Boron (DPD) in the absence of boron treatment using the indirect immunohistochemical method. The evaluation of these staining was done using the H-scoring system. Results: It was found that immunoreactivities of VEGF, eNOS, and iNOS increased on control compared to those of the cells of MDA-MB231 human breast cancer cell line. Following boron derivatives treatment, it was observed that they were inhibited the VEGF/NOS labeling in MDA-MB-231 breast cancer cells. Conclusion: The present data suggest that BP, especially DPD, inhibits the angiogenesis of breast cancer cells through VEGF pathway. From this point, these boron derivatives may provide a novel therapeutic approach for breast cancer treatment.

🔖

Bu Makaleye Atıf Yap

ŞİMŞEK, F., İNAN, S., KORKMAZ, M. (2019). An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 1, 22–27. https://ajindex.com/articles/129124

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 2004;88:141–8
  2. Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E. Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 2010;76:13–35
  3. Scorei R, Ciubar R, Ciofrangeanu CM, Mitran V, Cimpean A, Iordachescu D, et al. Comparative effects of boric acid and calcium fructoborate on breast cancer cells. Biol Trace Elem Res 2008;122:197–205
  4. Pizzorno L. Nothing boring about boron. Integr Med (Encini- tas) 2015;14:35–48
  5. Barranco WT, Eckhert CD. Boric acid inhibits human prostate cancer cell proliferation. Cancer Lett 2004;216:21–9
  6. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190–200
  7. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett 2012;316:126–31
  8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76
  9. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794–814
  10. Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K, et al. Angiopoietin pathway gene expression associated with poor breast cancer survival. Breast Cancer Res Treat 2017;162:191–8
  11. Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W, et al. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine 2017;12:6075–88
  12. Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M, Sahebkar A, et al. Vascular endothelial growth factor: An important molecular target of curcumin. Crit Rev Food Sci Nutr 2017;1–14. doi: 10.1080/10408398.2017.1366892. [Epub ahead of print]
  13. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436–41
  14. Eroğlu A, Ersöz C, Karasoy D, Sak S. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis. Adv Clin Exp Med 2017;26:245–9
  15. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression.